PSN 010

Drug Profile

PSN 010

Alternative Names: LY 2599506; PSN010

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Prosidion
  • Developer Eli Lilly
  • Class Antihyperglycaemics
  • Mechanism of Action Glucokinase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Suspended Type 2 diabetes mellitus

Most Recent Events

  • 15 Dec 2016 Biomarkers information updated
  • 15 Sep 2011 Final adverse events and pharmacodynamics data from a phase I trial in Type-2 diabetes mellitus presented at the 47th Annual meeting of the European Association for the Study of Diabetes (EASD-2011)
  • 24 Jun 2010 Suspended - Phase-II for Type-2 diabetes mellitus in Australia (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top